Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: Recommendations of the Polish Adult Leukemia Group

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 6, 2008, Pages 356-361

  Giebel, Sebastian ^a   Krawczyk Kuliś, Małgorzata ^a   Adamczyk Cioch, Maria ^b   Czyz, Anna ^c   Lech Marańda, Ewa ^d   Pia̧tkowska Jakubas, Beata ^e   Paluszewska, Monika ^f   Pałynyczko, Grazyna ^g   Piszcz, Jarosław ^h   Hołowiecki, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^h MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute lymphoblastic leukemia; Central nervous system

Indexed keywords

CYTARABINE; CYTOSTATIC AGENT; DEXAMETHASONE; METHOTREXATE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; POLAND; PRACTICE GUIDELINE; PROGNOSIS; RADIATION DOSE; REVIEW; SPINAL CORD; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 46949107063     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.414     Document Type: Review

References (28)

1. Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program, 2006; 142-146.
2. Mahmoud HH, Rivera G, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993; 329: 314-319.
3. Mastrangelo R, Poplack D, Bleyer A, et al. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol. 1986; 14: 194-194.
4. Fière D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1993; 11: 1990-2001.
5. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL-XII/ECOG E2993. Blood. 2006; 108: 465-472.
6. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001; 15: 208-216.
7. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999; 17: 2461-2470.
8. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004; 22: 3916-3921.
9. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999; 17: 3110-3116.
10. Bleyer WA. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin Cancer Res. 1999; 5; 3349-3351.
11. Surapaneni UR, Cortes JE, Thomas D. et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer., 2002; 94: 773-779.
12. Neale GA, Pui CH, Mahmoud HH, et al. Molecular evidence for minimal residual bone marrow disease in children with isolated extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia. 1994; 8: 768-775.
13. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995; 86: 2091-2097.
14. Omura GA, Moffitt S, Vogler WR, Salter MM. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood. 1980; 55: 199-204.
15. Blaney SM, Poplack DG, Godwin K, et al. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995; 13: 177-179.
16. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid (CSF) examination in children with acute lymphoblastic leukemia (ALL): significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003; 21: 184-188.
17. Gajjar A, Harrison PL, Sandlund JT, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000; 96: 3381-3384.
18. Dutch Childhood Oncology Group, te Loo DM, Kamps WA, Does-van den Berg AV, et al. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: the experience of the Dutch Childhood Oncology Group. J Clin Oncol. 2006; 24: 2332-2336.
19. Jabbour E, O'Brien S, Kantarjian H. et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007; 109: 3214-3218.
20. McClune B, Buadi FK, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma. 2007; 48: 1849-1851.
21. Pui CH. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma. 2007; 48: 1672-1673.
22. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003; 349: 640-649.
23. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia. 2000; 14: 2257-2266.
24. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002; 99: 863-871.
25. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809-3817.
26. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL 97 randomized trial. Br J Haematol. 2005; 129: 734-745.
27. Hołowiecki J, Krawczyk-Kuliś M, Giebel S, et al. Zajȩcie ośrodkowego układu nerwowego w przebiegu ostrej białaczki limfoblastycznej jako czynnik prognostyczny co do nawrotu po autologicznej transplantacji szpiku. Acta Haematol Pol. 1998; 29 (Suppl. 2): 30.
28. Wojnar J, Giebel S, Hołowiecka-Goral A, et al. Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia. Pol Arch Med Wewn. 2006; 116: 671-677.